Exchange: NYSEArca·Updated 07:48 PM EDT
News
all
press releases
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.
Stocktwits
More News
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs
Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Stocktwits
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?
Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.
Stocktwits
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain
The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.
Stocktwits
AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies
AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies PR Newswire BETHESDA, Md...
PR Newswire
ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat
Enveric stated during after-market hours on Thursday that it has entered into definitive agreements for the purchase and sale of 2.2 million shares of its common stock at a purchase price of $2.25.
Stocktwits
ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug
For the fourth quarter of 2025, the company reported net loss attributable of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.
Stocktwits
Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength
The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”
Stocktwits
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors
Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.
Stocktwits

Advertisement|Remove ads.